Clinical trial · no report yet · Phase 1
NCT05701709
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
- NCT05701709 ↗
- Recruiting
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- 4 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- An Open-Label, Single-Arm, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of SHR-A2102 in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- SHR-A2102
- Arms
- SHR-A2102 · Experimental
- Enrollment
- 395 (estimated)
- Primary outcomes
- Number of participants with adverse events
- Maximum tolerated dose (MTD)
- Recommended Phase 2 dose (RP2D)
- Dose Limiting Toxicity (DLT)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Start
- Apr 6, 2023
- Primary completion
- Aug 31, 2025 (estimated)
- Results posted
- No
- Registry record
- NCT05701709 · updated Jul 22, 2025
Publications
linked from the registry- Zhong R, Hong H, Yan M, Wang Q, Zhang Y, Lan Q, Luo Y, Zhang L, Xu H, Guo S, Guo W, Ma J, Zhang L, Wu L, Liu Z, He W, Sun Y, Chen K, Huang J, Han G, Nian W, Zhang M, Ren S, Qiao R, Li X, Yu M, Hu J, Huang Y, Song L, Shi W, Zhong H. SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial. Lancet Oncol. 2026 Sep;27(9):1146-1157. doi: 10.1016/S1470-2045(26)00238-X. PubMed 42636836